Pelotonia Institute for Immuno-Oncology launched at Ohio State to fight cancer at all levels

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) today announced formation of the Pelotonia Institute for Immuno-Oncology (PIIO), a comprehensive bench-to-bedside research initiative focused on harnessing the body's immune system to fight cancer at all levels-;from prevention to treatment and survivorship.

Pelotonia, a grassroots cycling event that has raised more than $190 million for cancer research initiatives at the OSUCCC – James has pledged more than $102 million over the next five years. The largest portion of the pledge – $65 million – will directly fund the PIIO, with the remaining dollars continuing to support well established initiatives such as Pelotonia Fellowships, Idea Grants, statewide research initiatives and equipment. The OSUCCC – James is also supporting the PIIO with a $35 million commitment to grow and sustain modern research infrastructure.

Zihai Li, MD, PhD, a physician scientist and elected member of American Society for Clinical Investigation (ASCI) and Association of American Physicians (AAP), has been recruited to lead the new institute. Li joins Ohio State from the Medical University of South Carolina Hollings Cancer Center, where he served as the Sally Abney Rose Endowed Chair in Stem Cell Biology & Therapy, co-leader of the Cancer Immunology program and as chair of the Department of Microbiology and Immunology.

The OSUCCC – James expects to add up to 32 additional faculty over the next five years to work within the PIIO. Multi-phase laboratory renovations will take place during this time to create advanced cellular laboratory facilities, immune monitoring and discovery platforms, immunogenomics, systems immunology, and other research areas for start-up initiatives and national collaborations with other academic centers and industry partners. Li's appointment as the founding director of the PIIO will help Ohio State build upon the already strong endeavors in immunotherapy, which is widely considered to be the next frontier in cancer treatment.

"Building this institute is a bold, forward-thinking leap that we expect to move the mark on drug discoveries in immuno-oncology in a significant way," says OSUCCC Director Raphael Pollock, MD, PhD. "This effort will allow us to make fundamental discoveries to develop next generation immuno-oncology agents, expand existing cellular therapy research facilities, offer pilot funding for new research projects and training opportunities for students and junior faculty."

In 2009, 2,265 riders showed up for the inaugural Pelotonia ride. They believed in the potential of this community and we honor their vision and dedication. Today, we are thrilled to make this transformational commitment to an area of research with such profound promise – immuno-oncology. We hope that this pledge inspires our community to do what they do best – to go above and beyond to achieve something that none of us could do on our own."

Doug Ulman, President and CEO of Pelotonia

This initiative will continue to leverage the innovative and collaborative work of scientists from both the OSUCCC – James and Nationwide Children's Hospital.

The institute adds to the existing track record of success in cancer research, prevention and care at central and southern Ohio's only National Cancer Institute (NCI)-designated comprehensive cancer center.

The OSUCCC – James is a pillar of strength at Ohio State and in our community. Through the cancer center, we conduct multi-disciplinary research spanning medicine, engineering, food science, public health and other disciplines in the health sciences. This transformative gift will allow for an entirely new level of collaboration, research and discovery at our university – a level only possible at a comprehensive institution like Ohio State."

President Michael V. Drake, MD.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Panthera’s oncology clinical trial sites in the UK are open for research activities